Overall Survival Results for Encorafenib Plus Binimetinib in BRAF-Mutant Melanoma
Keith T. Flaherty, MD, professor of Medicine, Harvard Medical School, director of Clinical Research, Massachusetts General Hospital, discusses overall survival results from the phase III COLUMBUS trial investigating encorafenib plus binimetinib versus vemurafenib (Zelboraf) or encorafenib in BRAF-mutant melanoma during the 2018 ASCO Annual Meeting.
Keith T. Flaherty, MD, professor of Medicine, Harvard Medical School, director of Clinical Research, Massachusetts General Hospital, discusses overall survival (OS) results from the phase III COLUMBUS trial investigating encorafenib plus binimetinib versus vemurafenib (Zelboraf) or encorafenib inBRAF-mutant melanoma during the 2018 ASCO Annual Meeting.
Earlier results showed the median progression-free survival rate for the combination of encorafenib and binimetinib was just under 15 months, which is a few months longer than what has been achieved with any other melanoma therapy that has recently emerged. Strikingly, the median OS was just over 33 months, which is also markedly longer than what has previously been seen. These results represent quite a striking milestone in this disease, Flaherty says.
